Business Wire

MA-REINVEST-ROBOTICS

8.12.2021 13:02:06 CET | Business Wire | Press release

Share
Proposed “European AI Act” and “Machinery Product Regulation” Will Hamper Innovation, Stifle Small Businesses and Disrupt Manufacturing, Global Robotics Leaders Warn

The European Commission’s proposed AI Act and updated regulations on machinery products will cause severe damage to European small businesses, robotics companies and innovation, according to four of the most influential voices in robotics and automation. Together, the International Federation of Robotics , the VDMA Robotics + Automation Association , EUnited Robotics and REInvest Robotics urgently call on European policymakers to revisit and amend the proposals.

While all four organizations embrace the European Commission’s vision to maintain safety, protect human rights and create a harmonized framework for artificial intelligence and robotics, the collective sees the following primary issues with the proposed regulations as currently drafted:

  • The mandatory third-party certification requirements will slow tech innovation across Europe.
  • The restrictions will hinder artificial intelligence adoption and put European companies, especially SMEs and startups, at a competitive disadvantage globally.
  • Disruption risk to regional supply chain, manufacturing and logistics operations will rise if the proposals are implemented and adopted.
  • Compliance with regulation worldwide will become more complex and burdensome.

Dr. Susanne Bieller, General Secretary of the International Federation of Robotics, states, “The International Federation of Robotics calls on European policymakers to amend both drafts to balance the protection of citizens with the market’s need to adopt new technologies and ensure a level-playing field for companies. This is not purely a European issue, as the proposed regulations will severely impact all companies bringing robots to the European market. In the long run, the new regulations will be to the disadvantage of European companies, especially SMEs and startups.”

Patrick Schwarzkopf, Managing Director of the VDMA Robotics + Automation Association and Director of EUnited Robotics, comments: “The EU-Commission’s proposals include burdensome regulations of so-called ‘High-Risk AI’ and ‘High-Risk-machinery.’ They include the introduction of extensive mandatory third-party certification requirements, which will discourage the use of AI and slow down innovation across Europe.”

Dr. Esben Hallundbæk Østergaard, the CEO of REInvest Robotics and founder of Universal Robots, comments: “The proposed legislation will hold back European robotics innovation. This is particularly concerning given robotics is the one emerging tech segment where Europe still has an edge globally. Locally, the legislation will negatively affect thousands of small businesses, factories, and manufacturers that rely on robotics and AI to automate critical operations and overcome labor shortages.”

Recommended policy amendments include limiting the scope of the AI Act to essential human rights risks, relying on manufacturers’ self-declaration of conformity in both the AI-Act and Regulation on Machinery Products, increasing enforcement and governance of the existing approach of the machinery directive, and working to create a global framework that increases safety and ethics while maintaining a level playing field. The recent draft report published on the Regulation on Machinery products by the European Parliament’s Committee on Internal Market and Consumer Protection (IMCO) points in this direction by proposing to uphold the crucial principle of self-declaration.

“The approach of the current machinery directive is sufficient. The problem is with governance. We recommend focusing on ensuring that products on the market actually comply with the current EU law, not creating new regulations,” said Østergaard.

For more info, visit reinvestrobotics.com and watch Patrick Schwarzkopf and Dr. Esben Hallundbæk Østergaard discuss the proposals: https://youtu.be/cd0VQx6w-wQ

About REInvest Robotics

REInvest Robotics is a specialized accelerator that invests in startups that democratize the use of robotics to solve real world problems. Founded by robotics pioneer and inventor Esben Hallundbæk Østergaard and Richa Hallundbæk Misri, REInvest Robotics’ vision is to fuel the robotics ecosystem with sustainable investments and help entrepreneurs uplift humankind through robotics. The firm – which provides seed funding and advisory services – specializes in robotics, AI, manufacturing, safety standards and legislation. Successful investments include market leaders Universal Robots and Mobile Industrial Robots (MiR). Learn more at https://www.reinvestrobotics.com/ and follow REInvest Robotics on LinkedIn .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye